Skip to main content

Plasmodium Falciparum

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
Malaria Vaccine RTS,S/AS01EPhase 2Vaccine
RTS, S/AS01BPhase 2
Sanaria
SanariaMD - Rockville
1 program
1
Plasmodium falciparum SporozoitePhase 11 trial
Active Trials
NCT01001650Completed80Est. Sep 2010
GSK
GSKLONDON, United Kingdom
2 programs
Malaria Vaccine RTS,S/AS01EPHASE_2Vaccine1 trial
RTS, S/AS01BPHASE_21 trial
Active Trials
NCT04661579Completed620Est. Aug 2022
NCT00197054Completed255Est. Sep 2006
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
PpPfs25/ISA51 & ScPvs25/ISA51PHASE_11 trial
Active Trials
NCT00295581Completed0Est. Jun 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKMalaria Vaccine RTS,S/AS01E
GSKRTS, S/AS01B
SanariaPlasmodium falciparum Sporozoite
Allergy TherapeuticsPpPfs25/ISA51 & ScPvs25/ISA51

Clinical Trials (4)

Total enrollment: 955 patients across 4 trials

NCT04661579GSKMalaria Vaccine RTS,S/AS01E

Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy

Start: Nov 2020Est. completion: Aug 2022620 patients
Phase 2Completed
NCT00197054GSKRTS, S/AS01B

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Start: Jul 2005Est. completion: Sep 2006255 patients
Phase 2Completed
NCT01001650SanariaPlasmodium falciparum Sporozoite

Clinical Trial of the PfSPZ Vaccine

Start: Apr 2009Est. completion: Sep 201080 patients
Phase 1Completed
NCT00295581Allergy TherapeuticsPpPfs25/ISA51 & ScPvs25/ISA51

PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria

Start: Mar 2005Est. completion: Jun 20080
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.